MAC
SRPT icon

Mason & Associates (California)’s Sarepta Therapeutics SRPT Stock Holding History

Mason & Associates (California)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,170
Closed -$191K – 140
2025
Q2 		$191K Buy
+11,170
New +$477K 0.04% 119

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mason & Associates (California)'s SRPT Position: Q3 2025 in Review

Mason & Associates (California) sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 11,170 shares — an estimated $191K sold.

Mason & Associates (California) first reported a position in SRPT in Q2 2025 and held it in 1 quarter. The position peaked at $191K in Q2 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Mason & Associates (California) reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mason & Associates (California) sold 11,170 Sarepta Therapeutics shares in Q3 2025, an estimated $191K.
  • Mason & Associates (California) first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mason & Associates (California)'s Sarepta Therapeutics position peaked at $191K in Q2 2025.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Mason & Associates (California)'s 13F filing for Q3 2025, filed 7 Nov 2025.